查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1735648

被忽视的热带疾病药物和疫苗的全球市场规模（按产品、疾病、地区和预测）

Global Neglected Tropical Diseases Drugs And Vaccines Market Size By Product (Drugs, Vaccines), By Disease (Lymphatic Filariasis, Echinococcosis, Leishmaniasis, Dracunculiasis, Dengue, Chikungunya), By Geographic Scope And Forecast
出版日期: | 出版商: Verified Market Research | 英文 202 Pages | 商品交期: 2-3个工作天内

价格
简介目录

被忽视的热带疾病治疗和疫苗的市场规模和预测

被忽视的热带疾病（NTD）治疗和疫苗的市场规模近年来一直以中等速度增长，增长率显着，预计在市场估计和预测期（2026年至2032年）内将大幅增长。

  • 被忽视的热带疾病 (NTD) 治疗和疫苗是专门设计用于预防、治疗或消除主要影响卫生资源有限的热带和亚热带地区人民的疾病的药物和免疫接种。
  • 疟疾、登革热、利什曼原虫症和血吸虫病是影响全球数百万人的疾病之一，其中大多数人生活在低收入国家。
  • NTD 药物旨在治疗由多种病原体引起的感染疾病，而疫苗旨在激活免疫系统并预防这些疾病的发生。
  • 此外，这些治疗方法针对的是那些通常比流行感染疾病受到较少关注和资金支持的疾病，在全球卫生计划中发挥着重要作用，从而促进了全球范围内健康差距的缩小和医疗保健机会的公平性。

全球被忽视的热带疾病药物和疫苗市场动态

影响被忽视的热带疾病药物和疫苗市场的关键市场动态是：

关键市场驱动因素

  • 全球健康倡议和增加资金筹措：由世界卫生组织、盖兹基金会和其他非政府组织主导的全球健康倡议正在增加对NTD研究和开发的资金和支持，旨在透过提供所需的治疗和疫苗来根除或控制某些疾病，从而推动市场发展。
  • 研发技术进步：生物技术和遗传学的进步正在加速NTD治疗方法和疫苗的研发。先进技术的运用正在加速新治疗方法和疫苗的研发，从而推动市场成长。
  • 提升认知度和政府支持：全球对被忽视热带疾病的认知度正在不断提升，各国政府和国际组织对抗击被忽视热带疾病的支持也不断增加。旨在预防、控制和消除被忽视热带疾病的国家卫生计画和政策正在推动对可行治疗方案的需求。
  • 合作与伙伴关係：政府、製药公司和非营利组织之间的策略合作对于NTD治疗和疫苗的开发和推广至关重要。这些合作改善了研究、资金筹措和治疗的可近性，从而显着促进了市场成长。

主要挑战

  • 製药公司财政奖励有限：由于被忽视的热带疾病主要影响欠低度开发国家的低收入人群，製药公司几乎没有商业性奖励投资研发。这种财政诱因的缺乏阻碍了创新有效药物的开发。
  • 复杂的药物研发流程：针对被忽视的热带疾病 (NTD) 的药物和疫苗研发流程复杂、成本高昂且耗时。挑战包括需要进行大规模临床研究、获得监管部门的核准，以及在受这些疾病影响最严重的地区进行研究的难度，所有这些都影响着市场的成长。
  • 分发和获取挑战：在偏远贫困地区分发有效药物和疫苗是一个主要问题。基础设施薄弱、医疗机构匮乏以及政治不稳定，可能会阻碍需要治疗的人获得治疗，从而限制现有解决方案的有效性。

主要趋势：

  • 加强官民合作关係关係 (PPP)：政府、私人企业和非营利组织之间的合作日益增加。这些合作充分利用了各自领域的优势，加快了被忽视的热带疾病 (NTD) 药物和疫苗的资金筹措、研发和分发，并促进了市场成长和宣传。
  • 重点在于疫苗研发：鑑于疫苗的预防特性和成本效益，人们越来越重视NTD疫苗的研究。 mRNA疫苗和重组疫苗等疫苗技术创新正在被研究用于预防这些疾病，并代表该领域的主要趋势。
  • 全球卫生倡议协助提升可近性：全球卫生计画日益重视提高被忽视的热带疾病（NTD）治疗和疫苗接种的可近性。为了最大限度地减轻被忽视的热带疾病（NTD）的全球负担，各方正在努力协商降低成本、加强供应链，并改善流行地区的医疗设施，这将影响市场动态。

目录

第一章 全球被忽视的热带疾病药物及疫苗市场介绍

  • 市场概览
  • 研究范围
  • 先决条件

第二章执行摘要

第三章：已验证的市场研究调查方法

  • 资料探勘
  • 验证
  • 第一手资料
  • 资料来源列表

第四章被忽视的热带疾病药物和疫苗的全球市场展望

  • 概述
  • 市场动态
    • 驱动程式
    • 限制因素
    • 机会
  • 波特五力模型
  • 价值链分析

第五章全球被忽视的热带疾病药物和疫苗市场（按产品）

  • 概述
  • 製药
  • 疫苗

第六章全球被忽视的热带疾病药物和疫苗市场（按疾病）

  • 概述
  • 淋巴丝虫病
  • 包虫病
  • 利什曼原虫症
  • 蜻蜓病
  • 登革热
  • 基孔肯雅热
  • 其他的

7. 全球被忽视的热带疾病药物和疫苗市场（按地区）

  • 概述
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 其他欧洲国家
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 其他亚太地区
  • 世界其他地区
    • 拉丁美洲
    • 中东和非洲

第八章全球被忽视的热带疾病药物和疫苗市场的竞争格局

  • 概述
  • 各公司市场排名
  • 主要发展策略

第九章 公司简介

  • Johnson & Johnson
  • GlaxoSmithKline
  • Sanofi
  • Novartis
  • Bayer
  • Eli Lilly and Company
  • Pfizer
  • AbbVie Inc.
  • Amgen Inc.
  • Gilead Sciences Inc.

第十章 重大进展

  • 产品发布/开发
  • 合併与收购
  • 业务扩展
  • 伙伴关係与合作

第十一章 附录

  • 相关调查
简介目录
Product Code: 35774

Neglected Tropical Diseases Drugs And Vaccines Market Size And Forecast

The Neglected Tropical Diseases Drugs And Vaccines Market size is growing at a moderate pace with substantial growth rates over the last few years and is estimated that the market will grow significantly in the forecasted period i.e.2026 to 2032.

  • Neglected Tropical Diseases (NTD) Drugs and vaccines are pharmaceuticals and vaccinations specifically designed to prevent, treat, or eradicate diseases that primarily affect populations in tropical and subtropical regions with limited access to healthcare resources.
  • Malaria, dengue fever, leishmaniasis, and schistosomiasis are among the diseases that affect millions of people globally, with the majority of them living in low-income nations.
  • NTD medicines are intended to treat infections caused by numerous pathogens, whilst vaccines attempt to activate the immune system and prevent the onset of these diseases.
  • Furthermore, these interventions play an important role in global health initiatives by targeting diseases that generally receive less attention and financing than more prominent infectious diseases, thereby reducing health inequities and promoting fairness in healthcare access on a worldwide scale.

Global Neglected Tropical Diseases Drugs And Vaccines Market Dynamics

The key market dynamics that are shaping the Neglected Tropical Diseases Drugs And Vaccines Market include:

Key Market Drivers

  • Increased Global Health Initiatives and Funding: Global health initiatives led by WHO, the Gates Foundation, and other non-governmental organizations have expanded financing and support for NTD research and development. This support seeks to eliminate or control certain diseases by supplying required treatments and vaccines, hence driving the market.
  • Technological Advancements in Research and Development: Advances in biotechnology and genetics have accelerated the discovery of treatments and vaccines for NTDs. The use of advanced techniques accelerates the discovery of novel treatment approaches and vaccines, driving market growth.
  • Rising Awareness and Government Support: There is an increasing global awareness of NTDs, which has led to increased government and international assistance for combating these diseases. National health programs and policies aimed at NTD prevention, control, and elimination promote the need for viable treatment solutions.
  • Collaborations and Partnerships: Strategic alliances among governments, pharmaceutical corporations, and non-profit groups are critical for the development and delivery of NTD treatments and vaccines. These alliances make research, funding, and therapy more accessible, hence contributing considerably to market growth.

Key Challenges:

  • Limited Financial Incentives for Pharmaceutical Companies: Neglected Tropical Diseases primarily affect low-income populations in underdeveloped nations, providing few commercial incentives for pharmaceutical corporations to invest in R&D. This lack of financial motive hampers the development of innovative and effective medicines.
  • Complex Drug Development Process: The drug and vaccine development process for NTDs is complicated, expensive, and time-consuming. Challenges include the requirement for extensive clinical studies, regulatory approvals, and the difficulty of doing research in the regions most impacted by these diseases, all of which impact market growth.
  • Distribution and Access Challenges: Effective medicine and vaccine distribution in remote and poor locations is a major concern. Poor infrastructure, a lack of healthcare facilities, and political instability make treatments inaccessible to individuals in need, limiting the effectiveness of available solutions.

Key Trends:

  • Increased Use of Public-Private Partnerships (PPPs): Collaborations between governments, commercial sector entities, and non-profit groups are increasing. These collaborations use the strengths of each sector to increase funding, research, and distribution efforts for NTD medications and vaccines, hence improving market growth and outreach.
  • Focus on Vaccine Development: Given vaccines' preventive nature and cost-effectiveness, there is a growing emphasis on NTD vaccine research. Innovations in vaccine technology, such as mRNA and recombinant vaccines, are being investigated to prevent these diseases, indicating a significant trend in the field.
  • Expanding Access Through Global Health Initiatives: Global health programs are increasingly focusing on improving access to NTD treatments and vaccinations. Efforts to negotiate lower costs, strengthen supply chains, and improve healthcare facilities in impacted areas aim to minimize the worldwide burden of NTDs, which will shape market dynamics.

Global Neglected Tropical Diseases Drugs And Vaccines Market Regional Analysis

Here is a more detailed regional analysis of the Neglected Tropical Diseases Drugs And Vaccines Market:

Asia Pacific:

  • According to VMR Analyst, Asia Pacific is estimated to dominate the Neglected Tropical Diseases Drugs And Vaccines Market during the forecast period. A large proportion of the global population is affected by Neglected Tropical Diseases (NTDs) in Asia Pacific. The high prevalence of these diseases in the region generates a need for effective treatments and vaccines, establishing Asia Pacific as a critical market for NTD therapies.
  • Governments and private sectors in the Asia-Pacific region are investing more in healthcare infrastructure and services. This includes major investment in NTD prevention, treatment, and eradication, which will help to boost the region's medication and vaccine markets.
  • The region has emerged as a hotspot for collaborative R&D initiatives aimed at NTDs, with partnerships comprising local governments, international health organizations, and pharmaceutical corporations. These agreements improve the development and availability of new therapies and vaccinations.
  • Furthermore, in Asia Pacific countries, improvements in healthcare access and delivery systems have made it easier to distribute and administer NTD treatments and vaccines. Enhanced healthcare infrastructure and higher healthcare spending help to explain the region's dominance in the NTD medicines and vaccines market.

Latin America:

  • In Latin America, governments and non-governmental organizations (NGOs) have launched comprehensive efforts to control and eliminate NTDs. These initiatives include mass drug administration campaigns and vaccination drives, which have considerably increased the demand for NTD-related pharmaceuticals and vaccines in the region.
  • Latin America benefits from international financing and cooperation to tackle NTDs. Global health organizations such as PAHO, WHO, and the Gates Foundation provide critical financial and technical support for medicine and vaccine research, development, and distribution, hence boosting market growth.
  • Latin America has experienced a surge in regional collaboration on NTD research and development. Consortia of local research institutions, universities, and pharmaceutical businesses are developing creative methods to combat NTDs, promoting local market growth.
  • Furthermore, the region's healthcare infrastructure and services are improving significantly, making it easier to deliver NTD treatments and vaccines. Improved healthcare systems, as well as increased healthcare access in rural and underprivileged areas, are significant drivers of Latin America's growing market for NTD interventions.

Middle East & Africa:

  • Due to socioeconomic and climatic variables, the Middle East and Africa (MEA) region has a high incidence of neglected tropical diseases. The high prevalence of NTDs creates an urgent need for effective medications and vaccines, accelerating market growth in this region.
  • MEA governments, with the backing of international health organizations, are increasingly focused on NTD control and elimination programs. These activities frequently include mass drug administration and immunization campaigns, which directly increase demand for NTD-related drugs.
  • Healthcare investments in the MEA region have increased significantly, with an emphasis on enhancing infrastructure and access. This includes investments in hospitals, clinics, and distribution networks for medications and vaccinations, which will expand the reach and impact of NTD interventions.
  • Furthermore, MEA countries and worldwide partners are collaborating to promote NTD research and development. These collaborations seek to develop and implement effective treatments and vaccinations adapted to the region's specific needs, hence promoting the growth of the NTD medications and vaccines market.

Global Neglected Tropical Diseases Drugs And Vaccines Market: Segmentation Analysis

The Global Neglected Tropical Diseases Drugs And Vaccines Market is segmented based on Product, Disease, And Geography.

Neglected Tropical Diseases Drugs And Vaccines Market, By Product

  • Drugs
  • Vaccines

Based on Product, the market is segmented into Drugs and Vaccines. The drugs segment is estimated to dominate the Neglected Tropical Diseases Drugs And Vaccines Market due to the acute requirement for therapy in affected people, medications are the primary intervention approach. Drugs are utilized not only for treatment but also for preventative chemotherapy in high-risk populations, which can be implemented faster than vaccine development and distribution. Furthermore, the wider choice of accessible pharmacological therapies for numerous NTDs, as opposed to vaccinations, which are only available for a few diseases, contributes to pharmaceuticals' bigger market share.

Neglected Tropical Diseases Drugs And Vaccines Market, By Disease

  • Lymphatic Filariasis
  • Echinococcosis
  • Leishmaniasis
  • Dracunculiasis
  • Dengue
  • Chikungunya
  • Others

Based on Disease, the market is segmented into Lymphatic Filariasis, Echinococcosis, Leishmaniasis, Dracunculiasis, Dengue, Chikungunya, and Others. The Dengue disease segment is estimated to hold the majority share in the forecast period in the Neglected Tropical Diseases Drugs And Vaccines Market owing to dengue fever's extensive prevalence in tropical and subtropical locations around the world, which affects millions of people each year. The disease's high occurrence rate, combined with the serious health issues it can bring, necessitates extensive research and development efforts for effective dengue vaccines and therapeutic medications. Furthermore, increasing public health initiatives and financing targeted at preventing dengue transmission, such as large-scale vaccination campaigns and community awareness programs, add to the need for dengue-related pharmaceutical products.

Key Players

  • The "Neglected Tropical Diseases Drugs And Vaccines Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are Johnson & Johnson, GlaxoSmithKline, Sanofi, Merck & Co., Novartis, Bayer, Eli Lilly and Company, Pfizer, AbbVie Inc., Amgen Inc., Gilead Sciences Inc., Mylan N.V., Teva Pharmaceutical Industries Ltd., and Roche Diagnostics International Ltd.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

  • Global Neglected Tropical Diseases Drugs And Vaccines Market Recent Developments
  • In March 2024, the World Health Organization (WHO) emphasized African health ministers' commitment to eliminating malaria deaths. This represents a larger effort to control diseases that frequently overlap with neglected tropical diseases, even if it is not a direct NTD medicine or vaccine.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL NEGLECTED TROPICAL DISEASES DRUGS AND VACCINES MARKET

  • 1.1 Overview of the Market
  • 1.2 Scope of Report
  • 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

  • 3.1 Data Mining
  • 3.2 Validation
  • 3.3 Primary Interviews
  • 3.4 List of Data Sources

4 GLOBAL NEGLECTED TROPICAL DISEASES DRUGS AND VACCINES MARKET OUTLOOK

  • 4.1 Overview
  • 4.2 Market Dynamics
    • 4.2.1 Drivers
    • 4.2.2 Restraints
    • 4.2.3 Opportunities
  • 4.3 Porters Five Force Model
  • 4.4 Value Chain Analysis

5 GLOBAL NEGLECTED TROPICAL DISEASES DRUGS AND VACCINES MARKET, BY PRODUCT

  • 5.1 Overview
  • 5.2 Drugs
  • 5.3 Vaccines

6 GLOBAL NEGLECTED TROPICAL DISEASES DRUGS AND VACCINES MARKET, BY DISEASE

  • 6.1 Overview
  • 6.2 Lymphatic Filariasis
  • 6.3 Echinococcosis
  • 6.4 Leishmaniasis
  • 6.5 Dracunculiasis
  • 6.6 Dengue
  • 6.7 Chikungunya
  • 6.8 Others

7 GLOBAL NEGLECTED TROPICAL DISEASES DRUGS AND VACCINES MARKET, BY GEOGRAPHY

  • 7.1 Overview
  • 7.2 North America
    • 7.2.1 U.S.
    • 7.2.2 Canada
    • 7.2.3 Mexico
  • 7.3 Europe
    • 7.3.1 Germany
    • 7.3.2 U.K.
    • 7.3.3 France
    • 7.3.4 Rest of Europe
  • 7.4 Asia Pacific
    • 7.4.1 China
    • 7.4.2 Japan
    • 7.4.3 India
    • 7.4.4 Rest of Asia Pacific
  • 7.5 Rest of the World
    • 7.5.1 Latin America
    • 7.5.2 Middle East and Africa

8 GLOBAL NEGLECTED TROPICAL DISEASES DRUGS AND VACCINES MARKET COMPETITIVE LANDSCAPE

  • 8.1 Overview
  • 8.2 Company Market Ranking
  • 8.3 Key Development Strategies

9 COMPANY PROFILES

  • 9.1 Johnson & Johnson
    • 9.1.1 Overview
    • 9.1.2 Financial Performance
    • 9.1.3 Product Outlook
    • 9.1.4 Key Developments
  • 9.2 GlaxoSmithKline
    • 9.2.1 Overview
    • 9.2.2 Financial Performance
    • 9.2.3 Product Outlook
    • 9.2.4 Key Developments
  • 9.3 Sanofi
    • 9.3.1 Overview
    • 9.3.2 Financial Performance
    • 9.3.3 Product Outlook
    • 9.3.4 Key Developments
  • 9.4 Novartis
    • 9.4.1 Overview
    • 9.4.2 Financial Performance
    • 9.4.3 Product Outlook
    • 9.4.4 Key Developments
  • 9.5 Bayer
    • 9.5.1 Overview
    • 9.5.2 Financial Performance
    • 9.5.3 Product Outlook
    • 9.5.4 Key Developments
  • 9.6 Eli Lilly and Company
    • 9.6.1 Overview
    • 9.6.2 Financial Performance
    • 9.6.3 Product Outlook
    • 9.6.4 Key Developments
  • 9.7 Pfizer
    • 9.7.1 Overview
    • 9.7.2 Financial Performance
    • 9.7.3 Product Outlook
    • 9.7.4 Key Developments
  • 9.8 AbbVie Inc.
    • 9.8.1 Overview
    • 9.8.2 Financial Performance
    • 9.8.3 Product Outlook
    • 9.8.4 Key Developments
  • 9.9 Amgen Inc.
    • 9.9.1 Overview
    • 9.9.2 Financial Performance
    • 9.9.3 Product Outlook
    • 9.9.4 Key Developments
  • 9.10 Gilead Sciences Inc.
    • 9.10.1 Overview
    • 9.10.2 Financial Performance
    • 9.10.3 Product Outlook
    • 9.10.4 Key Developments

10 KEY DEVELOPMENTS

  • 10.1 Product Launches/Developments
  • 10.2 Mergers and Acquisitions
  • 10.3 Business Expansions
  • 10.4 Partnerships and Collaborations

11 Appendix

  • 11.1 Related Research